Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme - A Review of Trials

被引：0
|
作者：
Pruthi, Deep Shankar [1 ]
Nagpal, Puneet [1 ]
Pandey, Manish [1 ]
机构：
[1] Act Canc Hosp, Dept Radiat Oncol, A-4, New Delhi, India
来源：
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY | 2021年 / 5卷 / 03期
关键词：
Adjuvant; Glioblastoma Multiforme; Extended duration; Temozolomide; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; PROLONGED TEMOZOLOMIDE; OPEN-LABEL; RADIOTHERAPY; CONCOMITANT; SURVIVAL; THERAPY;
D O I：
10.14744/ejmo.2021.20733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
引用
收藏
页码：217 / 221
页数：5
相关论文
共 50 条
  • [21] ELUCIDATION OF RESISTANCE TO TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME
    Hiddingh, Lotte
    Tops, Bastiaan
    Hulleman, Esther
    Kaspers, Gert-Jan L.
    Vandertop, W. Peter
    Wesseling, Pieter
    Noske, David P.
    Wurdinger, Tom
    Jeuken, Judith W.
    NEURO-ONCOLOGY, 2011, 13 : 78 - 79
  • [22] The efficacy of temozolomide for recurrent glioblastoma multiforme
    Chen, Chao
    Xu, Tao
    Lu, Yicheng
    Chen, Juxiang
    Wu, Shenhong
    EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (02) : 223 - 230
  • [23] Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?"
    Balana, Carmen
    Carrato, Cristina
    Angeles Vaz, Maria
    NEURO-ONCOLOGY, 2020, 22 (12) : 1889 - 1890
  • [24] Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma
    Pitz, M. W.
    Lipson, M.
    Hosseini, B.
    Lambert, P.
    Guilbert, K.
    Lister, D.
    Schroeder, G.
    Jones, K.
    Mihalicioiu, C.
    Eisenstat, D. D.
    CURRENT ONCOLOGY, 2012, 19 (06) : 308 - 314
  • [25] Temozolomide and thalidomide in the treatment of glioblastoma multiforme
    Riva, M.
    Imbesi, F.
    Begh, E.
    Gallp, C.
    Citteri, A.
    Trapani, P.
    Sterzil, R.
    Collice, M.
    ANTICANCER RESEARCH, 2007, 27 (02) : 1067 - 1071
  • [26] Improved survival of patients with glioblastoma multiforme by temozolomide as adjuvant therapy: A retrospective cohort study
    Wang, T. H.
    Wei, K. C.
    Wang, J. D.
    VALUE IN HEALTH, 2008, 11 (03) : A56 - A56
  • [27] Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Balana, Carmen
    Sun, Chen
    Angeles Vaz, Maria
    Esteve, Anna
    NEURO-ONCOLOGY, 2021, 23 (09) : 1616 - 1618
  • [28] Effect of adjuvant extended temozolamide treatment in survival of patients with glioblastoma multiforme
    Yildirim, Berna Akkus
    Sumbul, Ahmet Taner
    Topkan, Erkan
    Ozdemir, Yurday
    Besen, Ali Ayberk
    Guler, Ozan Cem
    Sedef, Ali Murat
    Onal, Cem
    CUKUROVA MEDICAL JOURNAL, 2018, 43 (03): : 640 - 645
  • [29] Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: A 6-year experience.
    Buttolo, L.
    Giunta, F.
    Ferrari, V. D.
    Grisanti, S.
    Marini, G.
    Mortini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 60S - 60S
  • [30] Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
    Besiroglu, Mehmet
    Demir, Tarik
    Shbair, Abdallah T. M.
    Yasin, Ayse Irem
    Topcu, Atakan
    Turk, Haci Mehmet
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (08): : 932 - 936
12345